Lantheus Receives Transitional Pass-Through Payment Status For PYLARIFY TruVu Injection From Centers For Medicare & Medicaid Services, Effective Oct. 1
Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better
Lantheus got special payment approval for a new medical imaging drug. This means hospitals can use it starting in October and get paid.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.